Navigation Links
Managing symptoms by mobile phone may revolutionize cancer care for young people
Date:6/10/2008

eeling, what their temperature is, what symptoms they have and it includes a body outline so that the patient can indicate where the pain is. The language used is teenage-friendly and the whole system has been developed with the help of young patients.

The symptom reports are sent to a central server and nurses at the hospital can view them on a web page. The patient can also view their symptoms on the phone in the form of graphs, which show how their symptoms have changed over time. Once they have reported symptoms, the young person automatically receives a text message giving them advice about what to do. In the latest phase of development, the patient can click on a button that immediately gives them advice about management of the most common symptoms such as constipation, diarrhoea, sickness etc. If the symptoms are severe or getting worse, a nurse is automatically paged to contact the patient at home to offer advice and support.

Dr Gibson said that during the first stages of development, young people were very positive about the system. "They could really see the benefits and really liked it. When we were recruiting for the phase three trial, the young people who were randomised not to receive the phone were disappointed that they would not be able to use it." So far, it has been tested in teenagers aged 13-18 with lymphoma, soft tissue sarcoma and bone tumours, but the researchers hope to extend it to different groups, such as patients with leukaemia.

Teenagers said that it was useful because it gave them a record of their symptoms to talk about when they attended clinic: "Sometimes you may forget what symptoms you had three weeks ago," said one. It also saved them from having to continuously repeat their symptoms to different people at different times, and it meant that the patients knew that the doctors and nurses knew exactly what they were going through.

Parents commented on the system's potential to provide support and
'/>"/>

Contact: Emma Mason
wordmason@mac.com
44-077-112-96986
Teenage Cancer Trust
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. Oncologists are critical in managing psychiatric disorders in patients with advanced cancer
2. Methadone and systematic follow-up: the best solution for managing chronic pain
3. Roy Jakobs Appointed Elsevier Managing Director, A&G Sales and Customer Marketing
4. Empowerment Program Gets Patients on the PATH to Managing the Physical and Emotional Effects of Psoriatic Arthritis
5. Call Center Excellence: Managing Service-To-Sales Cultural Transformation
6. XRoads Solutions Group Appoints Dr. Ogan Gurel as Managing Director
7. Casey Family Programs Hires Ken Patterson as Managing Director of Child and Family Services
8. Managing the Service-to-Sales Cultural Transformation - Complimentary Excerpt Available from Best Practices
9. American College of Gastroenterology Offers Updated Clinical Guidance for Managing Pregnant Patients
10. National Nature Made(R) Survey Finds U.S. Adults Are Concerned About Heart Disease but May not be Managing Their Risk
11. Genstar Capital Appoints Mark Hanson to Managing Director
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2009)Midbrook,s advanced Technology Center helps companies develop and test their cleaning processes. The technology available to the lab allows it to work in a variety of industries and solve problems for
(Date:12/4/2009)PALO ALTO, Calif., Dec. 4 Varian Medical Systems (NYSE: VAR ) announced today that its Board of Directors has set the regular 2010 Annual Meeting of Stockholders for February 11, 2010 with a record
(Date:12/4/2009)PEMBROKE, Bermuda, Dec. 4 Allied World Assurance,Company Holdings, Ltd (NYSE: AWH ) today announced that Scott Carmilani,President and Chief Executive Officer, and Jack Sennott, Executive Vice,Pres
(Date:12/4/2009)MADISON HEIGHTS, Mich., Dec. 4 The Editorial Advisory and Securities Review Committee of BetterInvesting Magazine today announced Allergan, Inc. (NYSE: AGN ) as its February 2010 "Stock to Stud
(Date:12/4/2009)Late recurrence is a risk for some pediatric cancers, particularly Ewing sarcomas and tumors of the central nervous system, according to a new study published online December 4 in the Journal of the
Breaking Medicine News(10 mins):Health News:Midbrook Lab Testing Provides Results for Cleaning Process Develop and Verification 2Health News:Midbrook Lab Testing Provides Results for Cleaning Process Develop and Verification 3Health News:Varian Medical Systems Schedules Annual Stockholder Meeting in Palo Alto 2Health News:Allied World to Present at the 2009 Goldman Sachs U.S. Financial Services Conference 2Health News:BetterInvesting Magazine Releases February Stock to Study and Undervalued Stock Choicesfor Investors' Informational and Educational Use 2
...developed a way to produce blood vessels by engine... Researchers at the University at Buffalo D...y that the bone marrow is an excellent source of a... applications. According to Dr. Stelios T....
...e University of Nottingham are amassing an arsenal... against the most deadly of hospital superbugs . .... Its defences are so strong it can resist most an...hcare Associated Infections (CHAI), with Dr Peter ...
...niversity researcher is experimenting with ways to...hat we like about our favourite snacks . S...nce and industry at K-State's College of Agricultu... this process can be used to make fibre-enriched f...
...found that women are the real bosses at home . ...s, wives have greater power in marriage problem-so... 72 married couples from Iowa, found that wives, o... not considering who raised the topic. As...
...ting dads will be given some tips on how to raise ... The British government is hoping that its 23milli...et technology to support parents will appeal to fa...w initiative, "Parent Know-How", parents will be a...
...ho killed his 25-year-old female neighbor was sent...of Alicia Ross by her neighbor Daniel Sylvester w...ousness, by an Ontario Superior Court judge who im...er in the death of Alicia Ross, intended to kill h...
Other Medicine News:Health News:New Blood Vessels can Be Created from Bone Marrow Stem Cells: Study 2Health News:The Hospital Superbugs 2Health News:The Hospital Superbugs 3Health News:Now, Fibre-enriched Tasty Snacks in the Making 2Health News:Women are the Real Bosses at Home 2Health News:Women are the Real Bosses at Home 3Health News:A Savage Murderer in Canada Gets Sentenced to Life 2
(Date:12/4/2009)LAKE FOREST, Ill., Dec. 4 Hospira, Inc. (NYSE: HSP ), a leading global specialty pharmaceutical and medication delivery company, today announced the launch of its next-generation 50 mL and 100 mL V
(Date:12/4/2009)BILLERICA, Mass., Dec. 4 Axsun Technologies, Inc., a wholly-owned subsidiary of Volcano Corporation (Nasdaq: VOLC ), today announced the initial development and successful testing of a novel integra
(Date:12/4/2009)BETHESDA, Md., Dec. 4 Drs. Neal Shore and E. David Crawford presented results for prostate-specific antigen (PSA) recurrence from the additional analysis of secondary end points of biochemical recurr
Breaking Medicine Technology:Hospira Expands VisIV(TM) Portfolio to Offer Complete Range of Environmentally Friendly I.V. Containers 2Hospira Expands VisIV(TM) Portfolio to Offer Complete Range of Environmentally Friendly I.V. Containers 3Hospira Expands VisIV(TM) Portfolio to Offer Complete Range of Environmentally Friendly I.V. Containers 4Axsun Technologies, A Wholly-Owned Subsidiary of Volcano Corporation, Announces Breakthrough Integrated Light Source Architecture for Optical Coherence Tomography (OCT) Imaging 2Axsun Technologies, A Wholly-Owned Subsidiary of Volcano Corporation, Announces Breakthrough Integrated Light Source Architecture for Optical Coherence Tomography (OCT) Imaging 3Axsun Technologies, A Wholly-Owned Subsidiary of Volcano Corporation, Announces Breakthrough Integrated Light Source Architecture for Optical Coherence Tomography (OCT) Imaging 4Axsun Technologies, A Wholly-Owned Subsidiary of Volcano Corporation, Announces Breakthrough Integrated Light Source Architecture for Optical Coherence Tomography (OCT) Imaging 5Degarelix (FIRMAGON(R)) vs Leuprolide (Lupron Depot(R)) in Patients With Advanced Prostate Cancer: Further Analysis From a Phase III Pivotal Trial 2Degarelix (FIRMAGON(R)) vs Leuprolide (Lupron Depot(R)) in Patients With Advanced Prostate Cancer: Further Analysis From a Phase III Pivotal Trial 3Degarelix (FIRMAGON(R)) vs Leuprolide (Lupron Depot(R)) in Patients With Advanced Prostate Cancer: Further Analysis From a Phase III Pivotal Trial 4Omega 3 fatty acids appear to impact AMD progression 8896 1Omega 3 fatty acids appear to impact AMD progression 8896 2Omega 3 fatty acids appear to impact AMD progression 8896 3The Leukemia 26 Lymphoma Society Calls for Blood Cancer Research Program at the Department of Defense 49377 1The Leukemia 26 Lymphoma Society Calls for Blood Cancer Research Program at the Department of Defense 49377 2Bioheart to Introduce Improved Heart Failure Monitoring Systems at Heart Failure Nurses Annual Meeting 49375 1Bioheart to Introduce Improved Heart Failure Monitoring Systems at Heart Failure Nurses Annual Meeting 49375 2Bioheart to Introduce Improved Heart Failure Monitoring Systems at Heart Failure Nurses Annual Meeting 49375 3
... SUNNYVALE, Calif., April 13 Pharmacyclics, In...egun treating patients in a Phase,1 dose-escalatio... PCI-32765,an orally available, selective inhibito...al treatment for patients with relapsed or refract... the first Btk selective inhibitor to,be tested in...
... NOVATO, Calif., April 13 Raptor Pharmaceuticals ...ard: RPTP) today announced the appointment of Patr...r ("CMO"). Dr. Rioux will be responsible for the c...nical-stage drug development programs. , , (Logo:...YM074LOGO ) , , Raptor,s clinical programs inc...
Other Medicine Technology:Pharmacyclics Initiates Phase 1 Clinical Trial of Novel Oral Btk Inhibitor for Refractory B-cell Non-Hodgkin's Lymphoma 2Pharmacyclics Initiates Phase 1 Clinical Trial of Novel Oral Btk Inhibitor for Refractory B-cell Non-Hodgkin's Lymphoma 3Pharmacyclics Initiates Phase 1 Clinical Trial of Novel Oral Btk Inhibitor for Refractory B-cell Non-Hodgkin's Lymphoma 4Pharmacyclics Initiates Phase 1 Clinical Trial of Novel Oral Btk Inhibitor for Refractory B-cell Non-Hodgkin's Lymphoma 5Raptor Pharmaceuticals Appoints Dr. Patrice P. Rioux as Chief Medical Officer 2Raptor Pharmaceuticals Appoints Dr. Patrice P. Rioux as Chief Medical Officer 3Raptor Pharmaceuticals Appoints Dr. Patrice P. Rioux as Chief Medical Officer 4Raptor Pharmaceuticals Appoints Dr. Patrice P. Rioux as Chief Medical Officer 5
...al reference laboratory and a worldwide leader in ...UP offers an extensive test menu of highly complex... pathology. Owned by the University of Utah, ARUP ...e nation's university teaching hospitals and child...
...al reference laboratory and a worldwide leader in ...UP offers an extensive test menu of highly complex... pathology. Owned by the University of Utah, ARUP ...e nation's university teaching hospitals and child...
...al reference laboratory and a worldwide leader in ...UP offers an extensive test menu of highly complex... pathology. Owned by the University of Utah, ARUP ...e nation's university teaching hospitals and child...
...al reference laboratory and a worldwide leader in ...UP offers an extensive test menu of highly complex... pathology. Owned by the University of Utah, ARUP ...e nation's university teaching hospitals and child...
Medicine Products: